Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
Jun 9, 2026, 11:36

Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations

Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:

”The FDA has approved our treatment for hemophilia A and B for two new patient populations following a priority review.

With this approval, children ages 6 to 11 with hemophilia B will have a subcutaneous, non-factor treatment option available for the first time.

Read our press release.

Bringing a medicine discovered and developed by Pfizer to the people who need it most—guided at every step by patient need—is an important moment for our teams.

A special thank you to the Pfizer scientists who are continuing to advance care for people with hemophilia, and to the hemophilia patient community who participated in clinical trials that are instrumental to making advancements like this one happen.”

Proceed to the video attached to the post.

Stay updated with Hemostasis Today.